Pipeline

One platform: Multiple programs targeting intractable solid tumors

Imvax is leveraging its unique immunotherapy platform to develop a pipeline of personalized, whole tumor-derived treatments targeting intractable solid tumors, which represent a majority of adult cancers.

Target validation
IND-enabling
Phase 1
Phase 2
Phase 3

IGV-001 Glioblastoma

Glioblastoma multiforme (glioblastoma, or GBM) is a brain cancer that is nearly always fatal. It is the most common malignant tumor that affects the central nervous system (CNS) and overall the third most common tumor of the brain and CNS.

A person newly diagnosed with GBM has a median overall survival (OS) or life expectancy of 12 to 15 months, and less than 6% of GBM patients survive to five years after diagnosis. The current standard of care treatment is based on surgery to remove as much of the tumor as possible. Surgery is typically followed by radiotherapy and chemotherapy.

IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma which in total dosed 46 patients. In the Phase 1b study, IGV-001 was well tolerated and multiple efficacy signals were observed. These included significant improvements in progression-free survival, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response.

A randomized, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma will be initiated in the fourth quarter of 2022.

IHC-001 Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is estimated that approximately 42,000 new cases will be diagnosed in the U.S. in 2021 per the American Cancer Society.

The five-year survival rate for patients diagnosed with HCC is about 20%.

Imvax is developing IHC-001 for the treatment of HCC. Preclinical studies are ongoing.

IEC-001 Endometrial Cancer

Endometrial cancer is the most common type of uterine cancer. The American Cancer Society estimates that there will be roughly 66,000 new cases of endometrial cancer in the United States this year, with an estimated number of deaths of almost 13,000. Endometrial cancers primarily affect post-menopausal women and the average age of diagnosis is 60.

Imvax is developing IEC-001 for treatment of endometrial cancer. Preclinical studies are ongoing.

IUC-001 Urothelial Cancer

Urothelial cancer is by far the most common type of bladder cancer. The American Cancer Society estimates that 81,180 new cases of bladder cancer will be identified in 2022 in the United States, with 75% of those cases occurring in men. Approximately 17,000 Americans will die from bladder cancer this year.

Imvax is developing IUC-001 for treatment of urothelial cancer. Preclinical studies are ongoing.

IOC-001 Ovarian cancer

Ovarian cancer is the fifth most deadly cancer among women in the U.S. according to the American Cancer Society. The ACS estimates that approximately 22,000 women in the U.S. are diagnosed annually, and approximately 14,000 women died of the disease in the U.S. in 2020.

Based on recent data, the five-year survival rate for Stage III-IV ovarian cancer is 25%.

Imvax is developing IOC-001 for the treatment of ovarian cancer. Preclinical studies are ongoing.

ICC-001 Colorectal carcinoma

Colorectal cancer, or cancer that begins inside the colon or rectum, is the second most common cause of cancer-related deaths in the U.S. Roughly 151,000 new cases of colorectal cancer are expected to be diagnosed in 2022, according to the American Cancer Society. The number of estimated deaths due to colorectal cancer in 2022 is almost 53,000.

Imvax is developing ICC-001 for treatment of colorectal cancer. Preclinical studies are ongoing.

Imvax clinical trials

Imvax’s story began with a physician’s dedicated pursuit of new hope for patients with a deadly cancer. Today, our team is driven by that same mission: to deliver transformational outcomes for people living with cancer through a new approach to personalized immunotherapy.

Patients’ care has always been at the center of our work. We are committed to the highest standards of professional excellence as we strive to rapidly advance a portfolio of investigational therapies, in collaboration with our network of clinical professionals.

As a company, we are obligated to ensure the safe and proper use of our investigational therapies and to provide access at the appropriate time, in the right manner and under the guidance of regulatory authorities, specifically the U.S. Food and Drug Administration (FDA).

If you or your physician have general questions regarding Imvax or our clinical work, or would like to connect with one of our patient advocates, please contact us at contact@imvax.com.

Imvax’s clinical studies can always be viewed at the database provided by clinicaltrials.gov.